Member Info for Herring

Will be interesting to see if we get a positive response to the RNS

Interesting shift in direction, I’m back in profit. Has someone leaked some news?

NAV finally out and discount is eye wateringly huge. At some point I might even make a profit

Can you two put a sock in it. GKP discussion or leave the room

I felt the same, no actual numbers bandied around. I don’t think the market will like it

Yeah I’m a master of the art form of understatement. A better description would be an absolute shocker of a RNS. I await the results with trepidation

Not the most positive of updates. Hopefully the market won’t pan it today

So NAV 208.9 share price 116, no debt no borrowings. Am I missing something here, negative sentiment, previous poor management?

I’m not sure we’re going to see the giddy heights of £15. We have the uncertainty of the demerger of the consumer healthcare side of the business to go through in 2022. It could be very choppy times ahead if the market feels they got rid of the consistent cash generating part of the business and the pharma/R&D part doesn’t deliver.

I've already sold having banked the dividend and £3 per share profit. My hope is for a retracement and a reentry point around 3000 with a view to selling next year at 3500.

Interesting, a buy back. Not many free shares about, most held by II's or the board.

Update very positive, operations in line with expectations.

Went into auction twice. Someone knows something?

http://www.investegate.co.uk/Article.aspx?id=201205170700225237D

http://www.investegate.co.uk/Article.aspx?id=201103090700115812C finals out, pretty decent set of results.

i doubt given the results they will try any further trials on juvista. they have £44M in cash which won't cover the trials they already have pencilled in for the current pipeline. It may be cash now, but in one years time they will require further funding including any payments due from big pharma deals. the costs of trials especially phase 3 are staggering.

it will be interesting to see how they justify the failure. It also calls into question the success of any other tissue healing drugs within their portfolio. its does seem surprising that it failed to meet any of the trial endpoints. i would love to hear from the CEO why it failed and the reason for so many positives soundbites from him, including previous trial failures were due to the doseage administered.

juvista appears to have failed both primary and secondary trial endpoints.

has there been any more details on when this is likely to happen? what is likely to be the effect on the sp as this will make it ISAble, or has this been factored in already?

if you're still a little wary, try a practice trading account first, its not real money and will get you used to the trading platform but also to share price movements. while you do this decide on what you want out of trading. if its solid growth with dividends stay away from risky oil and miners on the AIM and stick to shares in the FTSE350. if its short term investing with a greater degree of risk, then look into AIM, but do your own research and dont follow the advice of others, its your money and then you cant blame anyone else if it goes wrong! good luck whatever you do, its fun and dont lose any sleep over it.